Eton Pharmaceuticals secures U.S. commercialization rights to IMPAVIDO® for $4.25M fixed fees

Eton Pharmaceuticals, Inc.

Eton will pay $4.25M in fixed fees ($125k Jul 2026, then $1.25M Apr 2027, etc.) plus up to $4M in milestone payments based on cumulative net sales.
Royalty rates: 55% of net sales up to $7M/year, 50% above $7M/year; Supplier covers product costs and regulatory, Eton covers sales and marketing.
Exclusive U.S. commercialization rights start September 26, 2026; IMPAVIDO® had 2025 U.S. sales of $8.1M (Symphony Health).
IMPAVIDO® is the first FDA-approved oral therapy for leishmaniasis (visceral, cutaneous, mucosal), a rare parasitic disease.
This expands Eton's rare disease portfolio to eleven commercial products (including ten prior).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Eton Pharmaceuticals, Inc. entered into Supply and Distribution Agreement for IMPAVIDO® with affiliate of Knight Therapeutics, Inc. valued at $4.25 million fixed fees plus up to $4.0 million sales milestones and 55%/50% net sales share (effective 2026-05-18).

Action: entry
Agreement: supply
Counterparty: affiliate of Knight Therapeutics, Inc.
Value: $4.25 million fixed fees plus up to $4.0 million sales milestones and 55%/50% net sales share
Effective: 2026-05-18

Exact text from the filing

On May 18, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a supply and distribution agreement for the United States commercialization rights to IMPAVIDO® (miltefosine) oral capsules with an affiliate of Knight Therapeutics, Inc. (“Supplier”).

View on SEC.gov

Browse all material agreements →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017799

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.